MYO1E: A Drug Target for Muscle-Related Diseases (G4643)

Target Name: MYO1E

NCBI ID: G4643

MYO1E

MYO1E: A Drug Target for Muscle-Related Diseases

Myosin-Ie (MYO1E), also known as unconventional myosin, is a protein that plays a critical role in muscle contraction and relaxation. It is a member of the myosin family, which is known for its role in the cytoskeleton of eukaryotic cells. Despite its importance, MYO1E is not well understood, and its function in muscle physiology is still a topic of debate.

One possible function of MYO1E is as a drug target or biomarker.MYO1E has been shown to play a role in muscle physiology, and its dysfunction has been linked to a number of muscle-related diseases, including muscular dystrophy, myopathies, and neurodegenerative diseases. As a drug target, targeting MYO1E may provide new insights into the mechanisms underlying these diseases and the potential for new treatments.

MYO1E as a drug target

MYO1E has been shown to play a role in a number of muscle-related diseases, including muscular dystrophy, myopathies, and neurodegenerative diseases. Its function in these diseases is not well understood, but its dysfunction is thought to contribute to muscle weakness and dysfunction.

One of the key functions of MYO1E is its role in the regulation of muscle contraction and relaxation. It is a critical protein for the proper functioning of the myosin heads, which are the structural units that power muscle contraction.MYO1E has been shown to interact with other proteins involved in muscle physiology, including the myosin light chain protein (MLA), which is responsible for generating the force of muscle contraction.

MYO1E dysfunction has been linked to a number of muscle-related diseases, including muscular dystrophy and myopathies. In muscular dystrophy,MYO1E is often absent or defective, leading to muscle weakness and dysfunction. In myopathies, MYO1E is often expressed at higher levels than in normal muscle tissue, but its function is not well understood.

MYO1E has also been shown to be involved in the regulation of muscle relaxation, which is an important aspect of muscle physiology. During muscle relaxation, the myosin heads separate from each other, allowing the muscle cell to stretch and relax. Without MYO1E, muscle relaxation is not normal, and this has been linked to muscle-related diseases.

MYO1E as a biomarker

In addition to its role in muscle physiology, MYO1E has also been shown to be a potential biomarker for a number of muscle-related diseases. Its expression has been shown to be associated with a number of muscle-related diseases, including muscular dystrophy, myopathies, and neurodegenerative diseases.

MYO1E has been shown to be expressed at higher levels in muscles than in other tissues, which suggests that it may be a useful biomarker for these diseases. Its expression has also been shown to be associated with the development of muscle-related diseases, which further supports its potential as a biomarker.

MYO1E as a drug target

Given its potential role in muscle physiology and its association with muscle-related diseases, targeting MYO1E may provide new insights into the mechanisms underlying these diseases and the potential for new treatments.

One approach to targeting MYO1E is to use small molecules that can modulate its function. For example, drugs that can inhibit the activity of MYO1E have been shown to be effective in treating

Protein Name: Myosin IE

Functions: Actin-based motor molecule with ATPase activity (PubMed:11940582, PubMed:36316095). Unconventional myosins serve in intracellular movements. Their highly divergent tails bind to membranous compartments, which are then moved relative to actin filaments. Binds to membranes containing anionic phospholipids via its tail domain. Involved in clathrin-mediated endocytosis and intracellular movement of clathrin-coated vesicles (PubMed:36316095). Required for normal morphology of the glomerular basement membrane, normal development of foot processes by kidney podocytes and normal kidney function. In dendritic cells, may control the movement of class II-containing cytoplasmic vesicles along the actin cytoskeleton by connecting them with the actin network via ARL14EP and ARL14

The "MYO1E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYO1E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets